Because the leukemic HIS mouse model described above has a functional human immune system and genetically-matched (autologous) primary B-ALL, this model was used to model CD19-targeted CAR T cell therapy (63). Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.